Upstream Bio

UPB · Nasdaq · United States

Share price · UPB

$2.08-4.77 (-69.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when UPB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-22.7%

    Nothing announced by UPB that day or the session before.

  2. 29 Oct 2026+9.7%
  3. 22 Oct 2026+6.8%

    Nothing announced by UPB that day or the session before.

  4. 16 Oct 2026-18.1%

    Nothing announced by UPB that day or the session before.

  5. 13 Oct 2026-14.9%
  6. 12 Oct 2026-11.3%

    Nothing announced by UPB that day or the session before.

  7. 3 Sep 2026-6.2%

    Nothing announced by UPB that day or the session before.

  8. 1 Jul 2026+5.2%

    Nothing announced by UPB that day or the session before.

  9. 8 Jun 2026-8.5%
  10. 13 Feb 2026-31.6%

Share of unusual movement by asset

For each asset, the share of UPB's own-move activity since 14 Oct 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
verekitug
events and moves
1521%
Other company news (earnings, financing, releases naming no asset)—5%
Sessions with no dated event—74%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
TSLP receptorMonoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
verekitugPhase 2Severe Asthma
Est. primary completion 2027-09 · NCT06966479 · CT.gov ↗
What to watch
October 2027 (1)
verekitugPhase 2Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-10 · NCT06981078 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

11 February 2026Topline resultverekitugPhase 2 VALIANT of verekitug in severe asthma met its primary endpoint
Upstream Bio · Source ↗
2 September 2025Topline resultverekitugPhase 2 VIBRANT (NCT06164704) of verekitug in CRSwNP met its primary endpoint
Upstream Bio · Source ↗

Financial reports

Quarterly & interim (10)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.4M$37M$47M+ $160M short-term inv.$41M-$54M operating cash flowreport ↗
View 9 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.8M$36M$79M+ $182M short-term inv.$40M-$36M operating cash flowreport ↗
2026-Q1$1.0M$37M$97M+ $198M short-term inv.$41M-$48M operating cash flowreport ↗
2025-Q3$0.7M$33M$72M+ $300M short-term inv.$34M-$22M operating cash flowreport ↗
2025-Q2$0.9M$38M$45M+ $348M short-term inv.$40M-$39M operating cash flowreport ↗
2025-Q1$0.6M$26M$71M+ $360M short-term inv.$27M-$41M operating cash flowreport ↗
2024-Q3$0.6M$15M$33M+ $188M short-term inv.$16M-$14M operating cash flowreport ↗
2024-Q2$0.5M$14M$47M$15M-$8.0M operating cash flowreport ↗
2024-Q1$0.6M$12M$32M$11M-$18M operating cash flowreport ↗
2023-Q3$0.6M$7.8M$47M$3.1Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.9M$137M$102M+ $240M short-term inv.$36M-$133M operating cash flowreport ↗

Upstream Bio reported full-year 2025 revenue of $2.85M, up 20.3% YoY, with R&D spend of $136.81M, up 117.3% YoY. The company posted a net loss of $143.44M for the year and ended the period with cash and cash equivalents of $101.58M.

The company highlighted a Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate Phase 3 dosing in both indications in Q1 2027. Reported business developments include positive top-line results from the Phase 2 VALIANT trial in severe asthma, additional Phase 2 VIBRANT analyses in CRSwNP, and ongoing enrollment in the Phase 2 VENTURE COPD trial, which is more than 60% enrolled. The company also stated that its cash position of $341.5M, including short-term investments, is expected to fund planned operations through 2027.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.4M$63M$326M+ $145M short-term inv.$16M-$59M operating cash flowreport ↗
2023-FY$2.4M$32M$26M+ $84M short-term inv.$5.1M-$38M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($105K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-16Ambrose Allison · General CounselOpen-market sale485$5.49$3KForm 4
2026-09-16Houghton Adam · Chief Business OfficerOpen-market sale700$5.49$4KForm 4
2026-09-16Sutherland Everett Rand · director, Chief Executive OfficerOpen-market sale2,095$5.49$12KForm 4
2026-09-16Deykin Aaron · Chief Medical OfficerOpen-market sale895$5.49$5KForm 4
2026-09-16GRAY MICHAEL · CFO and COOOpen-market sale853$5.49$5KForm 4
2026-06-16Ambrose Allison · General CounselOpen-market sale477$6.10$3KForm 4
2026-06-16Deykin Aaron · Chief Medical OfficerOpen-market sale895$6.10$5KForm 4
2026-06-16Houghton Adam · Chief Business OfficerOpen-market sale700$6.10$4KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 140 reporting institutions held 44.9M shares ($403.9M, 81.9% of shares outstanding).

#InstitutionSharesValue
1FMR LLC8,101,563$72.9M
2ORBIMED ADVISORS LLC5,693,589$51.2M
3BlackRock, Inc.3,370,689$30.3M
4Decheng Capital LLC2,724,868$24.5M
5ENAVATE SCIENCES GP, LLC2,459,703$22.1M
6VANGUARD CAPITAL MANAGEMENT LLC1,873,574$16.9M
7Y-Intercept (Hong Kong) Ltd1,000,631$9.0M
8FEDERATED HERMES, INC.979,758$8.8M
9GEODE CAPITAL MANAGEMENT, LLC950,617$8.6M
10MILLENNIUM MANAGEMENT LLC937,323$8.4M
11SEB Asset Management AB878,473$7.9M
12Bain Capital Life Sciences Investors, LLC867,211$7.8M
13Woodline Partners LP831,481$7.5M
14D. E. Shaw & Co., Inc.820,480$7.4M
15Parkman Healthcare Partners LLC786,783$7.1M